Clinical Trials Browser

OTHER × Lymphoma, B-Cell × Calcium Dobesilate × Clear all

Burkitt Lymphoma, Lymphoma, B-Cell

NCT05476770 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Biphenotypic, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00290498 2020-06-02

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Phase 2 Completed

67 enrolled 12 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT01722305 2019-07-22

Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

Phase 1 Completed

29 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Intraocular Lymphoma

NCT00413959 2018-09-19

VRCD

Phase 2 Terminated

12 enrolled 7 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Clinical Trials

Venetoclax Plus Inotuzumab for B-ALL

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

VRCD